Marnix Jonker

1 month ago | publications.ersnet.org | Jorine Hartman |Marnix Jonker |Rein Posthuma |Lowie E.G.W. Vanfleteren

IntroductionBronchoscopic lung volume reduction using endobronchial valves (EBV) has been shown to provide clinical benefits for patients with emphysema including improvements in lung function, exercise capacity, dyspnoea severity and quality of life [1]. Recently, there has been increased attention on the potential extrapulmonary effects of this treatment.